About Altathera Pharmaceuticals
Altathera Pharmaceuticals is a Healthcare company based in Chicago (United States) founded in 2009 by Brandon Kashfian. Alternative therapeutics for rare diseases and critical care are developed. Altathera Pharmaceuticals has raised $7.61 million across 6 funding rounds. Altathera Pharmaceuticals offers products and services including Sotalol IV. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Altathera Pharmaceuticals is a specialty pharmaceutical company focusing on critical care and alternative therapeutics. The company develops therapies for critical care patients and patients with rare disorders. Its product Sotalol IV is a sotalol hydrochloride injection for patients who are unable to take sotalol orally. The company recently published meta-analysis comparing the efficacy of sotalol and amiodarone for the treatment of atrial fibrillation in two settings found no statistical difference between the two drug
- Headquarters Chicago, United States
- Founders Brandon Kashfian
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website altathera.com
- Social LinkedIn X Facebook
- Total Equity Funding$7.61M (USD)
in 6 rounds
- Latest Funding Round$1.53M (USD), Series A
Aug 2019
Products & Services of Altathera Pharmaceuticals
Altathera Pharmaceuticals offers a comprehensive portfolio of products and services, including Sotalol IV.
Reformulated antiarrhythmic for shortening hospital stays in atrial fibrillation cases.
Funding Insights of Altathera Pharmaceuticals
Altathera Pharmaceuticals has successfully raised a total of $7.61M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $1.53 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.61M
- Total Rounds 6
- Last Round Series A — $1.53M
- First Round $500,000
(Jan 2015)
All 6 funding rounds of Altathera Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2019 | $1.53M | Series A | – | – | – |
| Dec 2016 | $3.35M | Series A | – | – | – |
| Nov 2016 | $225,000 | Seed | – | – | – |
| Jul 2015 | $1M | Seed | – | – | – |
| Feb 2015 | $1M | Seed | – | – | – |
| Jan 2015 | $500,000 | Seed | – | – | – |
People of Altathera Pharmaceuticals
14 people are tracked at Altathera Pharmaceuticals (7 in leadership, 2 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Brandon Kashfian | Founder | Leadership |
Adam Strickberger MD | Chief Medical Officer | Leadership |
Chris Condes | Vice President Of Strategy And Operations | Leadership |
Edward (Eddie) Kalmykov, Ph.D. | Vice President - Global Medical Affairs And Healthcare Solutions | Leadership |
John Ellis II | Chief Executive Officer | Leadership |
Stephen O'Sullivan | General Counsel, Chief Compliance Officer, Director | Leadership |
Sharon Fitzpatrick | Director Of People Operations - Interim | Leadership |
James Perry | Clinical & Scientific Advisor | Board & advisors |
T. Jared Bunch | Clinical & Scientific Advisor | Board & advisors |
Seth Stein | Regional Account Manager | Team |
Eric Benson | Corporate Development and Financial Planning & Analysis | Team |
Samantha Firmstone | Senior Medical Science Liaison | Team |
Rob Penington | Consultant | Team |
J. Reymond | Regional Development Manager | Team |
Complete people profiles for Altathera Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Altathera Pharmaceuticals
3 dated milestones of Altathera Pharmaceuticals across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Altathera Pharmaceuticals is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Series A, of $1.5M.
Competitors of Altathera Pharmaceuticals
Altathera Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Altathera Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Altathera Pharmaceuticals
The website of Altathera Pharmaceuticals (altathera.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 17.4% vs previous month
Websites whose visitors overlap most with Altathera Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medexus.com | 100% | 6.4K | #3,239,042 | View details | |
| xerispharma.com | 92% | 11.8K | #2,449,948 | View details |
Top companies in Rare Diseases
3 companies that operate in the same segment as Altathera Pharmaceuticals (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Altathera Pharmaceuticals
Complete news archive for Altathera Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Altathera Pharmaceuticals
Altathera Pharmaceuticals was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Altathera Pharmaceuticals is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Altathera Pharmaceuticals is a funded company, having raised a total of $7.61M across 6 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Jan 2015.
Altathera Pharmaceuticals is a specialty pharmaceutical company focusing on critical care and alternative therapeutics. The company develops therapies for critical care patients and patients with rare disorders. Its product Sotalol IV is a sotalol hydrochloride injection for patients who are unable to take sotalol orally. The company recently published meta-analysis comparing the efficacy of sotalol and amiodarone for the treatment of atrial fibrillation in two settings found no statistical difference between the two drug.
Altathera Pharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Altathera Pharmaceuticals offers Sotalol IV.